The results of this randomised, double-blind, double-dummy, placebo-controlled, parallel-group study demonstrate the efficacy of loratadine and fexofenadine in relieving the common symptoms of SAR ...
Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback